<DOC>
	<DOCNO>NCT01662102</DOCNO>
	<brief_summary>The purpose study evaluate effect consolidation treatment Zevalin® versus maintenance treatment Rituxan® progression-free survival ( PFS ) follow response induction chemotherapy plus rituximab previously untreated patient follicular lymphoma .</brief_summary>
	<brief_title>Rituximab Zevalin - Efficacy Trial Therapeutic Alternatives ( RoZetta )</brief_title>
	<detailed_description>This open-label , multicenter randomize study . Patients register response induction ( PR/CR ) R-chemotherapy . Patients achieve either PR CR follow R-chemotherapy eligible randomization either consolidation 90Y-ibritumumab tiuxetan follow observation 24 month , rituximab maintenance 24 month . After observation/maintenance period , patient follow 5 year . This study design similar ZAR2007 study ( EUDRACT No . 2007-006601-25 ) carry PETHEMA Spain . It expect Spanish center contribute 230 patient ; center US elsewhere contribute remain 254 patient . The randomization procedure use study . The total sample size combine study 484 randomized patient . Assuming PFS follow exponential distribution constant hazard rate , 36 month uniform accrual period additional follow-up time 60 month last patient randomize , 242 patient per arm ( 484 total ) necessary observe 131 PFS event combine study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>18 75 year age Previously untreated histologically confirm grade 1 , 2 3a CD20positive follicular lymphoma , GELF ( Groupe d'Etude de Lymphomes Folliculaires ) treatment criterion prior induction . Achieved response induction treatment either RCHOP ( 6 cycle RCHOP21 RCHOP14 ) , RCVP ( 6 cycle ) , RB ( 4 6 cycle ) . Must complete dos induction treatment , except modification allow protocol . Transformation high grade lymphoma ( secondary `` low grade '' FL ) Grade 3b follicular lymphoma Primary follicular lymphoma skin gastrointestinal tract Previous treatment follicular lymphoma Altered renal hepatic function Known HIV infection and/or active HBV and/or HCV infection Serious comorbid condition ( example , ongoing infection , uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease ) . Life expectancy &lt; 6 Must : Platelet count ≥ 100x109/L Bone marrow infiltration &lt; 25 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>